Amphastar Pharmaceuticals (AMPH) FY2018 results: revenue $295 million, up 22.7% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $295 million for fiscal 2018, the year ended 31 December 2018, up 22.7% on the year before. Net income was -$6 million, and diluted earnings per share $-0.12. The figures are the company's own, from the 10-K it filed with the SEC on 15 March 2019.
Revenue
$295 million
+22.7% on the year
FY2012FY2018
Operating margin
-2.9%
-0.5% a year earlier
FY2012FY2018
Net income
-$6 million
FY2012FY2018
Diluted EPS
-$0.12
FY2012FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
295
240
255
+22.7%
Cost of revenue
188
149
151
+25.6%
Gross profit
107
90.5
104
+18.2%
Gross margin
36.3%
37.7%
40.8%
Research and development
57.6
43.5
41.5
+32.3%
Operating income
-8.6
-1.3
15.4
Operating margin
-2.9%
-0.5%
6.0%
Interest expense
0.2
0.8
1.0
-70.6%
Pre-tax income
-9.9
1.2
14.6
Income tax
-3.3
-2.4
4.8
Effective tax rate
n/a
-192.0%
32.9%
Net income
-5.7
3.6
9.8
Net margin
-1.9%
1.5%
3.8%
Diluted EPS
-$0.12
$0.09
$0.21
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
38.2
39.2
38.6
-2.6%
Capital expenditure
46.8
35.1
21.4
+33.4%
Free cash flow
-8.6
4.1
17.2
Free cash flow margin
-2.9%
1.7%
6.7%
Cash from investing
-42.2
-36.9
-39.5
Cash from financing
25.0
-7.7
7.1
Depreciation and amortisation
6.1
6.4
14.7
-5.7%
Share-based compensation
16.7
17.1
15.1
-2.4%
Buybacks
25.0
30.7
9.9
-18.5%
Diluted shares, weighted
46m
48m
48m
-4.1%
Shares outstanding at period end
47m
47m
46m
+0.0%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
332
334
329
-0.4%
Non-controlling interest
31.9
n/a
n/a
Debt
49.1
45.7
36.0
+7.4%
Other liabilities
100
71.6
62.5
+39.8%
Total liabilities and equity
514
451
428
+13.9%
Fixed assets
210
181
153
+16.5%
Goodwill
4.0
4.5
4.0
-11.4%
Intangible assets
9.1
11.5
17.1
-20.6%
Investments
2.8
2.6
0.5
+7.4%
Cash and equivalents
86.3
65.6
72.4
+31.6%
Receivables
52.2
36.0
26.8
+44.9%
Inventory
69.3
63.6
79.8
+9.0%
Other assets
79.5
86.8
74.3
-8.4%
Total assets
514
451
428
+13.9%
10-K for the year ended 31 December 2018, filed 15 March 2019: the filing.